<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998283</url>
  </required_header>
  <id_info>
    <org_study_id>09-HM10460A-102</org_study_id>
    <nct_id>NCT00998283</nct_id>
  </id_info>
  <brief_title>Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study Design&#xD;
&#xD;
             -  Randomized, Double-blind, Placebo-controlled, escalating single-dose design.&#xD;
&#xD;
             -  Five ascending dose cohorts.&#xD;
&#xD;
             -  In each cohort, subjects will be randomized to receive a single dose of HM10460A or&#xD;
                placebo (negative control)&#xD;
&#xD;
        -  Objectives&#xD;
&#xD;
             -  The primary objective of the study is to assess the safety and tolerability of&#xD;
                single escalating subcutaneous doses of HM10460A in healthy adult Korean Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of the study are as follows:&#xD;
&#xD;
        -  to assess the pharmacokinetics (PK) of a single subcutaneous dose of HM10460A.&#xD;
&#xD;
        -  to assess the relationship between the serum concentration of HM10460A and absolute&#xD;
           neutrophil count (ANC).&#xD;
&#xD;
        -  to assess the relationship between the serum concentration of HM10460A and CD34+ cell&#xD;
           counts in the blood.&#xD;
&#xD;
        -  to assess the immunogenicity (HM10460A, native G-CSF antibody,neutralizing antibodies)&#xD;
           of a single subcutaneous dose of HM10460A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs, and adverse effects (AEs)</measure>
    <time_frame>Time point of collection, where appropriate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Samples for immunogenicity</measure>
    <time_frame>Time point of collection, where appropriate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum PK parameters/Urine PK parameters</measure>
    <time_frame>Serum : pre-dose, 0.25, 05, 0.75, 1,2,3,4,6,8,12,16,24,36,48,72,96,120,144 (hr)// Urine : 0-6, 6-12, 12-24, 24-36, 36,48(hr)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the ANC (Absolute Neutrophil count) &amp; CD34+ cell.</measure>
    <time_frame>Pre-dose, 24 and 48 hours post-dose, on return Days 4,5,6,7,11,15 and 22</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 5μg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 15μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 45μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 135μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 350μg/kg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 5μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 15μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 45μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 135μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 350μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult Korean male and/or females, 20 - 45 years of age(inclusive).&#xD;
&#xD;
          -  BMI of 18 - 27kg/m2.&#xD;
&#xD;
          -  Medically healthy with no clinically significant screening results.&#xD;
&#xD;
          -  The following results in laboratory test&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) : 2000 ~ 7500/mm3&#xD;
&#xD;
          -  Non-smokers or subjects who smoke less than 10 cigarettes/day&#xD;
&#xD;
          -  After a confirmed menstrual period, females of childbearing potential must be either&#xD;
             sexually inactive (abstinent) for 14 days prior to screening and agree to remain so&#xD;
             throughout the study, or have been using a highly effective method of birth control,&#xD;
             such as the following examples:&#xD;
&#xD;
               -  intra-uterine device in place for at least 3 months prior to Day 1;&#xD;
&#xD;
               -  stable hormonal contraceptive for at least 3 months prior to Day 1 through&#xD;
                  completion of study;&#xD;
&#xD;
               -  surgical sterilization (vasectomy) of partner at least 6 months prior to Day 1.&#xD;
&#xD;
          -  Females of non-childbearing potential must have undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to Day 1:&#xD;
&#xD;
               -  bilateral tubal ligation;&#xD;
&#xD;
               -  hysterectomy;&#xD;
&#xD;
               -  hysterectomy with unilateral or bilateral oophorectomy;&#xD;
&#xD;
               -  bilateral oophorectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             or psychiatric disease.&#xD;
&#xD;
          -  Positive urine drug/alcohol testing at screening or check-in.&#xD;
&#xD;
          -  Positive testing for HIV, HBsAg, or HCV antibodies.&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Positive testing for palpable spleen at screening or check-in.&#xD;
&#xD;
          -  The following results in laboratory test:&#xD;
&#xD;
               -  WBC &gt; 10.0 x 10^3/mm3&#xD;
&#xD;
               -  Hb &lt; 13g/dL&#xD;
&#xD;
               -  Platelet &lt; 150 x 10^3/mm3&#xD;
&#xD;
               -  AST/ALT &gt; 50 IU/L&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within 2 years prior to Day 1.&#xD;
&#xD;
          -  History of G-CSF-related product use (i.e., pegfilgrastim, filgrastim).&#xD;
&#xD;
          -  History of anaphylactic reaction to medicine or environmental exposures.&#xD;
&#xD;
          -  Use of any prescription medication (with the exception of hormonal contraceptives for&#xD;
             females) or receipt of any blood products within 14 days prior to Day 1.&#xD;
&#xD;
          -  Use of any over-the-counter medication, including herbal products, within 7 days prior&#xD;
             to the Day 1. Up to 2 grams per day of acetaminophen is allowed at the discretion of&#xD;
             the Investigator.&#xD;
&#xD;
          -  Blood donation or significant blood loss within 56 days prior to Day 1.&#xD;
&#xD;
          -  Plasma donation within 7 days prior to Day 1.&#xD;
&#xD;
          -  Participation in another clinical trial (receipt of last investigational medication)&#xD;
             within 30 days prior to Day 1.&#xD;
&#xD;
          -  Females who are pregnant or lactating.&#xD;
&#xD;
          -  Subjects who are unlikely to comply with the protocol requirements, instructions and&#xD;
             study related restrictions; e.g., uncooperative attitude, inability to return for&#xD;
             follow-up visits and improbability of completing the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Clinical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

